Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

Introduction: Molecular profiling is considered a standard of care in advanced NSCLC. A comprehensive next-generation sequencing panel can discover somatic or germline BRCA1/2 mutations that are new druggable molecular alterations. However, the phenotypic and potential therapeutic relevance of BRCA1...

Full description

Bibliographic Details
Main Authors: Jordi Remon, MD, Benjamin Besse, MD, PhD, Alexandra Leary, MD, PhD, Ivan Bièche, MD, Bastien Job, MD, Ludovic Lacroix, PhD, Aurélie Auguste, PhD, Marjorie Mauduit, PhD, Clarisse Audigier-Valette, MD, Judith Raimbourg, MD, Anne Madroszyk, MD, Stefan Michels, MD, Mohammed Amine Bayar, MD, Marta Jimenez, PhD, Jean-Charles Soria, MD, PhD, Etienne Rouleau, PhD, PharmD, MPH, Fabrice Barlesi, MD, PhD
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:JTO Clinical and Research Reports
Subjects:
BRCA mutation
Advanced non–small cell lung cancer
PARP inhibitors
Next-generation sequencing
SAFIR trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320300916

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320300916

Similar Items